Latest News

The Colton Center for Autoimmunity at Yale is pleased to announce the eleven 2024 Yale projects selected for their promising research in autoimmunity and allergic diseases. In addition to grant funding, Colton Center awardees receive mentorship, access to industry expertise, and feedback on their potential commercialization.

Rachel Bandler, MD, PhD, a third-year resident in the Yale Department of Psychiatry, has been selected to receive the 2024 National Institute of Mental Health (NIMH) Outstanding Resident Award.

“When the study launched, even with operable pancreatic cancers, 90% of patients were still relapsing and dying from their cancer eventually,” said Dr. Michael Cecchini, the first author of the study and the co-director of the colorectal program at the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and YCC. “We sought to move chemotherapy up in their treatment regimen and give it before surgery to see if we could improve the outcome for our patients.”

Solve President and CEO Emily Taylor, Chief Scientific Officer H. Timothy Hsiao, and Director of Advancement Ilise Friedman recently visited Yale School of Medicine’s Center for Infection & Immunity (CII), the Center Director, Sterling Professor Akiko Iwasaki, and her research team, as coordinated by Dr. Nicole Darricarrère, CII’s Scientific Program Director, in New Haven, CT. The Solve delegation honored Professor Iwasaki with an award to recognize her contributions to the study of infection-associated chronic conditions and illnesses, and delivered an invited talk to the Iwasaki Lab to elaborate the power of the Solve Together Real-World Platform to accelerate biomedical research for post-acute infection syndromes, such as ME/CFS and Long Covid.

Yale Cancer Center scientists and trainees attended the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 31-June 4 to present research advances from Yale Cancer Center and Smilow Cancer Hospital. The ASCO meeting is the most significant gathering of oncology professionals worldwide, initiating connections and forging collaborations that can change the landscape of cancer care.

The results of this trial, an overall response rate of 56.5% and a response rate of 75% at the highest dose level, are impressive for CAR-T therapy for a solid tumor, to be sure, said Sidi Chen, a cancer researcher at Yale Cancer Center who was not involved with the work.

Yale Cancer Center and Smilow Cancer Hospital people who have been honored

In a new study, published in the American Journal of Respiratory and Critical Care Medicine, researchers used single-cell RNA sequencing to measure the gene expressions of individual peripheral blood mononuclear cells in patients with progressive IPF, patients with stable IPF, and lung-disease-free patients. Previously, the researchers had studied bulk samples of these cells but not examined them individually and in detail.

DNA has received an immense amount of attention. And while the double helix was certainly groundbreaking in its time, the current generation of scientific history will be defined by a different (and, until recently, lesser-known) molecule: RNA. Mentions Yale's Sidney Altman.